Personal genetics startup 23andMe is reportedly considering expanding overseas to so it can get sales back on track despite its standoff with the FDA. The Google ($GOOG)-backed business was hit with an FDA warning letter last year, after which it stopped providing an analysis of health risks with its test results. With the FDA slowing progress in the U.S., 23andMe is looking into whether Australia, Canada or the United Kingdom would be more amenable to its tests, Reuters reports. Article